Karolina Kraska

Ms. Karolina Kraska

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2024 in Cells
Verified
Journal Article
Open access
PDF file
EBElżbieta Laura Bartoszewska
Elżbieta Laura Bartoszewska
MTMaciej Tota
Maciej Tota
MKMonika Kisielewska
Monika Kisielewska
ISIzabela Skowron
Izabela Skowron
KSKamil Sebastianka
Kamil Sebastianka
ACAnna Choromańska
Anna Choromańska
Leukemia is a prevalent pediatric cancer with significant challenges, particularly in relapsed or refractory cases. Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a personalized cancer treatment, modifying patients’ T cells to target and destroy resistant cancer cells. This study reviews the current therapeutic options of CAR-T therapy for leukemia, addressing the primary obstacles such as antigen escape and T-cell exhaustion. We explore dual-targeting strategies and their potential to improve treatment outcomes by preventing the loss of target antigens. Additionally, we examine the mechanisms of T-cell exhaustion and strategies to enhance CAR-T persistence and effectiveness. Despite remarkable clinical successes, CAR-T therapy poses risks such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Our findings highlight the need for ongoing research to optimize CAR-T applications, reduce toxicities, and extend this innovative therapy to a broader range of hematologic malignancies. This comprehensive review aims to provide valuable insights for improving leukemia treatment and advancing the field of cancer immunotherapy.

3 August 2024 in Molecules
Verified
Journal Article
Open access
PDF file
MSMikołaj Sędzik
Mikołaj Sędzik
KRKatarzyna Anna Rakoczy
Katarzyna Anna Rakoczy
JSJakub Jan Sleziak
Jakub Jan Sleziak
Michał KisielMichał Kisiel
Michał Kisiel
KKKarolina Kraska
Karolina Kraska
ACAnna Choromańska
Anna Choromańska
Exosomes and microvesicles bear great potential to broaden therapeutic options in the clinical context. They differ in genesis, size, cargo, and composition despite their similarities. They were identified as participating in various processes such as angiogenesis, cell migration, and intracellular communication. Additionally, they are characterized by their natural biocompatibility. Therefore, researchers concluded that they could serve as a novel curative method capable of achieving unprecedented results. Indeed, in experiments, they proved remarkably efficient in enhancing wound regeneration and mitigating inflammation. Despite immense advancements in research on exosomes and microvesicles, the time for their large-scale application is yet to come. This article aims to gather and analyze current knowledge on those promising particles, their characteristics, and their potential clinical implementations.